DEVANI

Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response

 Coordinatore GLAXOSMITHKLINE VACCINES SRL 

 Organization address address: Via Fiorentina 1
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Francesco
Cognome: Gulli
Email: send email
Telefono: -243627
Fax: -244102

 Nazionalità Coordinatore Italy [IT]
 Totale costo 5˙923˙577 €
 EC contributo 4˙196˙460 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-01-01   -   2011-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE VACCINES SRL

 Organization address address: Via Fiorentina 1
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Francesco
Cognome: Gulli
Email: send email
Telefono: -243627
Fax: -244102

IT (SIENA) coordinator 0.00
2    AARHUS UNIVERSITET

 Organization address address: Nordre Ringgade 1
city: AARHUS C
postcode: 8000

contact info
Titolo: Ms.
Nome: Lizzie
Cognome: Jensen
Email: send email
Telefono: 4589421642
Fax: 4589421112

DK (AARHUS C) participant 0.00
3    ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU

 Organization address address: VIA FIORENTINA 151
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Aldo
Cognome: Tagliabue
Email: send email
Telefono: 390577000000
Fax: 390577000000

IT (SIENA) participant 0.00
4    CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE

 Organization address address: Sart Tilman B35
city: LIEGE
postcode: 4000

contact info
Titolo: Dr.
Nome: Louis
Cognome: Pol
Email: send email
Telefono: 3243667000
Fax: 3243667007

BE (LIEGE) participant 0.00
5    HEALTH PROTECTION AGENCY HPA

 Organization address address: Central Office - 7th Floor, Holborn Gate - High Holborn 330
city: LONDON
postcode: WC1V 7PP

contact info
Titolo: Prof.
Nome: Peter S.
Cognome: Borriello
Email: send email
Telefono: 4402080000000
Fax: 4402080000000

UK (LONDON) participant 0.00
6    ISTITUTO SUPERIORE DI SANITA

 Organization address address: Viale Regina Elena 299
city: ROMA
postcode: 161

contact info
Titolo: Dr.
Nome: Rosa Maria
Cognome: Martoccia
Email: send email
Telefono: 390650000000
Fax: 390650000000

IT (ROMA) participant 0.00
7    NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES

 Organization address address: blvd. Yanko Sakazov 26
city: SOFIA
postcode: 1504

contact info
Titolo: Prof.
Nome: Bogdan
Cognome: Petrunov
Email: send email
Telefono: 35929400000000
Fax: 35929433075

BG (SOFIA) participant 0.00
8    Servicio Andaluz de Salud

 Organization address address: AVENIDA DE LA CONSTITUCION 18
city: SEVILLA
postcode: 41071

contact info
Titolo: Dr.
Nome: Arturo D.
Cognome: Dominguez Fernandez
Email: send email
Telefono: 34958020245
Fax: 34958020132

ES (SEVILLA) participant 0.00
9    STATNI ZDRAVOTNI USTAV

 Organization address address: Srobarova 48
city: PRAHA 10
postcode: 10042

contact info
Titolo: Dr.
Nome: Jaroslav
Cognome: Volf
Email: send email
Telefono: 420267000000
Fax: 420267000000

CZ (PRAHA 10) participant 0.00
10    UNIVERSITAETSKLINIKUM FREIBURG

 Organization address address: HUGSTETTER STRASSE 49
city: FREIBURG
postcode: 79106

contact info
Nome: Gerhard
Cognome: Henninger
Email: send email
Telefono: +49 761 270 1920
Fax: +49 761 270 1889

DE (FREIBURG) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

strains    serotypes    adjuvant    gbs    first    inducing    protective    women    neonates    antibody    diseases    days    vaccine    birth    immune    protection    proteins    disease    immunization    group    maternal    neonatal    direct    streptococcus    cps   

 Obiettivo del progetto (Objective)

'Direct vaccination cannot prevent diseases that affect neonates in the first days of life. Group B Streptococcus (GBS) is the major cause of neonatal septicemia and meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that high titres of maternal antibody to GBS capsular polysaccharides (CPS) correlate with reduced risk of disease in neonates suggesting that maternal immunization may be an effective strategy for delivery of a protective immune response to the child in this early period. The overall objective of this proposal is to design immunization strategies capable of inducing strong durable and placentally transferable protective immune responses against GBS in women in order to fill this gap in early infancy when direct immunization is not possible. Starting with the genome sequence of 8 strains of GBS, Novartis scientists have identified three proteins that confer protection against lethal challenge in neonatal mice from immunized females. Combinations of CPS conjugates plus the recombinant proteins conferred protection against 12 of 12 GBS strains representing the major disease causing serotypes. In order to translate this research into a viable vaccine it will be necessary to identify appropriate adjuvant and delivery systems capable of inducing a protective response which will last through pregnancy. In order to select the serotypes of CPS to include in the vaccine, it will be necessary to understand the serotype distribution of GBS disease in Europe. Furthermore, an immune surrogate of protection will be required to replace efficacy trials. This proposal will address these issues by evaluating adjuvant and delivery in mouse models of disease and by analysis of maternal antibody levels and strain characteristics in cases versus controls obtained from several countries in Europe'

Introduzione (Teaser)

The idea of immunising women to deliver protective antibodies to their babies is gaining ground in the fight against many diseases. The goal of the DEVANI initiative was to utilise this approach for vaccinating against Group B Streptococcus (GBS) to promote protection in newborns.

Altri progetti dello stesso programma (FP7-HEALTH)

NEWTBVAC (2010)

Discovery and preclinical development of new generation tuberculosis vaccines

Read More  

BRAINTRAIN (2013)

Taking imaging into the therapeutic domain: Self-regulation of brain systems for mental disorders

Read More  

DENGUETOOLS (2011)

Innovative tools and strategies for surveillance and control of dengue

Read More